

Presentation of the proposed board members to the Annual General Meeting on May 19, 2026

According to the articles of association, the board of directors shall consist of not less than three and not more than seven members, with up to seven deputies. The Company's board of directors currently consists of four ordinary members, including the chairman. All board members and the deputy are elected for the period until the end of the next annual general meeting. Information about the board members follows below.

Jesper Høiland – born 1960, chairman since 2024

Education: MSc and BSc, Copenhagen Business School.

Experience: Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product launches and infrastructure building). Jesper has previously been a board member of Concert Pharma and Leo Pharma. Jesper has lived and worked in the US, Switzerland, Denmark, Australia, France, Belgium and Canada for the past 30 years.

Other current assignments: Strategic advisor to pharmaceutical and medical device companies. Member of the board of directors and the audit committee of ALK, member of the Board at Flen Health Group S.A., Allarity Therapeutics, Alva Therapeutics, chief of staff at Rani Therapeutics and CEO and founder of Pharmaco Consult Aps.A..

Independence: Jesper is independent in relation to the Company and its management as well as to major shareholders.

Holdings in SciBase: No of Shares: 6,719,108

Anna Eriksrud – born 1958, board member since 2025

Education: Bachelor of Science (BSc) in Business Administration and Economics, Uppsala University.

Experience: Anna has over 40 years of experience in the pharmaceutical industry as well as medical technology from mainly international work in the EU, USA, China and Japan. She has been involved in taking drugs from project status to blockbuster in the US, worked with orphan drug products for special diseases as well as consumer-driven products. Her entrepreneurial spirit in Life Science was realized by building a "Speciality Pharmacy", Apotekssamariten, when the Swedish reform allowed it in 2019. Companies where Anna has worked (including product launches, as CEO/General Manager, with IPO and then list change) include Pharmacia, Leiras/Schering, QMED (Galderma) and NeoDynamics. Anna has been stationed for several years in the Netherlands, the United States and the United Kingdom.

Other current significant assignments: Chairman of the Board in Prosperum Vitae AB and Board member in AcuCort AB.

Shareholding: Holder of 278,000 shares.

Independence: Anna is independent in relation to the Company and its management as well as to the Company's major shareholders.

Diana Ferro – born 1966, board member since 2017

Education: Diana holds an MBA from the University of Hamburg (MBA (Dipl.-Kffm.) – marketing and insurance) and has also taken various follow-on educations among them an exam in Medical Marketing from UCLA (University of California Los Angeles).

Experience: Diana has more than 25 years of international leadership experience in the MedTech and healthcare industry, with a strong focus on global commercialization and scaling of medical brands in regulated markets. She is CEO of MedSkin Solutions Dr. Suwelack AG, where she has led the company's international growth and long-term value creation across Europe, North America and Asia. Through more than 17 years in advanced medical skincare and biomaterials, Diana has developed a deep, clinically grounded understanding of skin health across multiple anatomical layers, spanning

epidermal and dermal structures, underlying soft tissue, and the interface to hard tissue (bone). This perspective bridges medical aesthetics, wound care and clinical dermatology. Previously, Diana held senior executive roles at KCI Medical (Acelity), including Vice President Global Marketing for VAC® Therapy, with global responsibility for a USD 1.47 billion franchise, and was a member of the International Operating Committee

Other current assignments: Board member of 4Sigma GmbH. CEO of Medskin Solutions Dr Suwelack AG.

Independence: Diana is independent in relation to the Company and the Company's management, as well as to the Company's major shareholders.

Holdings in SciBase: Holder of 272,272 shares.

Robert Molander - born 1965, board member since 2024

Education: MBA in Marketing and Finance, Washington University, John M. Olin School of Business and dual BA degrees in Economics and International Studies, Miami University.

Experience: Senior executive and advisor with over 25 years of experience in life science commercialization, primarily in the United States. Robert has held senior leadership roles at global pharmaceutical and life science companies including Novartis, Pfizer, Shionogi and Trialbee, with a focus on product launches, business development and the build-out of commercial organizations. He has previously served as Chief Commercial Officer of Infant Bacterial Therapeutics AB and Trialbee AB, and as a board member of Infant Bacterial Therapeutics AB.

Other current assignments: Board member of Xspray Pharma AB, Biosergen AB and CEO of Stratfox Healthcare Group LLC.

Independence: Robert is independent in relation to the Company and its management and to major shareholders.

Holdings in SciBase: No of Shares: 8,333,332.